{"id":44237,"date":"2022-05-23T22:01:18","date_gmt":"2022-05-23T20:01:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/"},"modified":"2022-05-23T22:01:18","modified_gmt":"2022-05-23T20:01:18","slug":"msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/","title":{"rendered":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC."},"content":{"rendered":"
\n

\nMSP Recovery, Inc. to Trade on Nasdaq Under the Symbol \u201cMSPR\u201d Starting May 24<\/i>\n<\/p>\n

CORAL GABLES, Fla.–(BUSINESS WIRE)–MSP Recovery, Inc. (\u201cMSPR\u201d), formerly known as Lionheart Acquisition Corporation II, a Delaware corporation (Nasdaq: LCAPU, LCAP, LCAPW, \u201cLionheart\u201d or \u201cLCAP\u201d), today announced that it has closed the previously announced business combination (the \u201ctransaction\u201d) with MSP Recovery, LLC. (\u201cMSP\u201d), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader. The business combination was approved by a majority of LCAP\u2019s stockholders in an extraordinary meeting on May 18, 2022.\n<\/p>\n

\nAs previously announced<\/a>, following the closing, LCAP\u2019s Class A Common Stock will cease trading on the Nasdaq Capital Market (\u201cNasdaq CM\u201d) under the symbol \u201cLCAP\u201d (CUSIP 53625R104), and will begin trading tomorrow — May 24, 2022 — on Nasdaq Global Market (\u201cNasdaq GM\u201d) under the symbol \u201cMSPR\u201d (CUSIP 553745100) and LCAP\u2019s warrants, each to purchase one share of Class A Common Stock of MSPR at $11.50 per share, will cease trading on the Nasdaq CM under the symbol \u201cLCAPW\u201d and begin trading on Nasdaq GM under the symbol \u201cMSPRZ\u201d.\n<\/p>\n

\n\u201cToday\u2019s news is the latest milestone showing that MSP Recovery has entered into an exciting new stage as one of the nation\u2019s most sophisticated and successful payer reimbursement recovery companies that continues to pave the way in discovering and recovering improperly paid claims as well as the development of cutting edge technology to fix the fragmented healthcare systems, to not only save tax payer dollars but also save lives,\u201d said MSP Recovery Founder and CEO, John H. Ruiz. \u201cThe closing of this business combination is proof of the confidence in the strength of our business strategy and effectiveness of our innovative approach. Since the announcement of the business combination agreement we have seen a substantial amount of new business over and above what we originally projected,\u201d said Mr. Ruiz.\n<\/p>\n

\nThe business combination with LCAP announced on July 12, 2021 was based on an enterprise value of the combined company of approximately $32.6 billion. The $32.6 billion valuation was based on projected MSPR Recovery Proceeds. Since July 2021, however, MSPR has been developing additional revenue streams.\n<\/p>\n

\nAs of December 31, 2021, MSPR\u2019s portfolio included more than $1.5 trillion in billed amount (reflecting the full amount billed by a provider to a health plan or insurer), up more than 530% from $242 billion in 2020. MSPR\u2019s portfolio included $364.4 billion in paid amount as of the same date (reflecting amounts actually paid to a provider from a health plan), up more than 520% from $58.4 billion in 2020.\n<\/p>\n

\nAnd since announcing the Business Combination in July 2021, MSPR has seen a significant increase in interest from various entities in the healthcare industry. During that time period alone, MSPR has: vetted 91 prospects; made proposals to 48 entities; conducted data diligence on 46 entities; generated a data evaluation report for 21 entities; and negotiated initial agreements with 20 entities. MSPR already has over 150 assignors, and continues to grow its number of assignors.\n<\/p>\n

\n\u201cI am thrilled to see this business combination successfully executed and look forward to working with John and the MSP Recovery team as they continue to innovate on behalf of a growing list of healthcare providers and payers,\u201d said Ophir Sternberg, Chairman and CEO of Lionheart. \u201cMSP Recovery is well-positioned to continue to expand its footprint in this promising market.\u201d\n<\/p>\n

\nAdvisors<\/b>\n<\/p>\n

\nKeefe, Bruyette & Woods, a Stifel Company, served as financial advisor to MSP Recovery. Nomura Securities International, Inc. served as financial and capital markets advisor to Lionheart Acquisition Corp II. Weil, Gotshal & Manges LLP served as legal counsel to MSP Recovery. DLA Piper LLP served as legal counsel to Lionheart Acquisition Corp II. ICR, LLC served as communications advisor to MSP Recovery.\n<\/p>\n

\nAbout MSP Recovery<\/b>\n<\/p>\n

\nFounded in 2014, MSP Recovery has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions, while innovating technologies to help save lives. For more information, visit: www.msprecovery.com<\/a>\n<\/p>\n

\nAbout Lionheart Acquisition Corporation II<\/b>\n<\/p>\n

\nLionheart Acquisition Corporation II was a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. For more information, visit: www.LCAP2.com<\/a>.\n<\/p>\n

\nCautionary Note Regarding Forward Looking Statements<\/b>\n<\/p>\n

\nThis communication includes forward looking statements within the meaning of the safe harbor from civil liability provided for such statements by the Private Securities Litigation Reform Act of 1995 (set forth in Section 21E of the Securities Exchange Act of 1934, as amended (\u201cExchange Act\u201d) and Section 27A of the Securities Act, which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements are often accompanied with or by words such as \u201cexpects\u201d, \u201cplans\u201d, \u201c projects\u201d,\u201d forecasts\u201d,\u201d estimates\u201d,\u201d intends\u201d, \u201cexpects\u201d, \u201canticipates\u201d, \u201cseeks\u201d, \u201c targets\u201d, \u201ccontinues\u201d, \u201c believes\u201d, \u201copinion\u201d, \u201cwill\u201d, \u201ccould\u201d, \u201cfuture\u201d, \u201cgrowth\u201d, or \u201cmay\u201d (or the negatives thereof) or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward looking statements include, but are not limited to, statements regarding MSP\u2019s plans, goals and objectives, forecasts, budgets or projections and any related assumptions and statements and the implied enterprise value and MSP\u2019s expectations with respect to future performance. There is no guarantee that prospects or results or the timing of events included or referred to in this communication, including the continued utilization of LifeWallet, or that it will save lives, will be achieved or that MSP will be able to implement successfully its investment strategy or achieve its investment objectives or return targets. Accordingly, we caution you against relying on forward-looking statements. Forward looking statements also are subject to a number of significant risks and uncertainties that could cause the actual results to differ materially, and potentially adversely, from those express or implied in the forward-looking statements. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are inherently subject to significant business, economic and competitive uncertainties and contingencies, and are beyond the control of MSP and are difficult to predict. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Factors that may cause such differences include, but are not limited to, operating costs and future business, investment, holding and sale decisions and costs; the risks that the anticipated benefits of the launch and adoption of LifeWallet are not realized or are delayed; the risks associated with MSP\u2019s business, including, among others, MSP\u2019s ability to capitalize on its assignment agreements and recover monies that were paid by the assignors; litigation results; the validity of the assignments of claims to MSP; a determination that MSP\u2019s claims are not reasonable, related or necessary; the failure of MSP\u2019s clients to renew their agreements with MSP (or terminate those agreements early); MSP\u2019s claims being within applicable statutes of limitations; the inability to successfully expand the scope of MSP\u2019s claims or obtain new data and claims from MSP\u2019s existing assignor base or otherwise; the limited number of MSP\u2019s assignors and the associated concentration of MSP\u2019s current and future potential revenue; internal improvements to claims and retail billing processes by MSP\u2019s clients that reduce the need for and revenue generated by MSP\u2019s products and services; healthcare spending fluctuations; programmatic changes to the scope of benefits and limitations to payment integrity initiatives that reduce the need for MSP\u2019s services; delays in implementing MSP\u2019s services to its claims; system interruptions or failures; cyber-security breaches and other disruptions that could compromise MSP\u2019s data; MSP\u2019s failure to maintain or upgrade its operational platforms; MSP\u2019s failure to innovate and develop new solutions, or the failure of those solutions to be adopted by MSP\u2019s existing and potential assignors; MSP\u2019s failure to comply with applicable privacy, security and data laws, regulations and standards, including with respect to third party providers; changes in legislation related to healthcare programs and policies; changes in the healthcare market; negative publicity concerning healthcare data analytics and payment accuracy; competition; successfully protecting MSP\u2019s intellectual property rights; the risk that third parties may allege infringement of their intellectual property; changes in the healthcare regulatory environment and the failure to comply with applicable laws and regulations or the increased costs associated with any such compliance; failure to manage MSP\u2019s growth; the inability to attract and retain key personnel; MSP\u2019s reliance on its senior management team and key employees and the loss it could sustain if any of those employees separated from the business; the failure of vendors and providers to deliver or perform as expected, or the loss of such vendors or providers; MSP\u2019s geographic concentration; MSP\u2019s relatively limited operating history, which makes it difficult to evaluate its current or future business prospects; the impact of the ongoing COVID-19 pandemic; and the risk that MSP may not be able to develop and maintain effective internal controls. The foregoing list of factors is not exhaustive. If any of these risks materialize or MSP\u2019s assumptions prove incorrect, actual results may differ materiality from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The foregoing list of factors is not exclusive. This communication speaks only as of the date indicated, and the statements, expressions, information and data included therein may change and may become stale, out-of-date or no longer applicable. We do not have, and do not undertake, any obligation to update, amend or revise this communication (or to provide new, amended or revised materials), including with respect to any forward-looking statements, whether as a result of new information, future events, changed plans or circumstances or any other reason, except as required by law. The communication should not be relied upon as representing our assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the communication, including the forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor Media:
\n
ICR, Inc.
\n
MSP@icrinc.com<\/a>\n<\/p>\n

\nFor Investors:
\n
ICR, Inc.
\n
Marc Griffin
\n
Marc.Griffin@icrinc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MSP Recovery, Inc. to Trade on Nasdaq Under the Symbol \u201cMSPR\u201d Starting May 24 CORAL GABLES, Fla.–(BUSINESS WIRE)–MSP Recovery, Inc. (\u201cMSPR\u201d), formerly known as Lionheart Acquisition Corporation II, a Delaware corporation (Nasdaq: LCAPU, LCAP, LCAPW, \u201cLionheart\u201d or \u201cLCAP\u201d), today announced that it has closed the previously announced business combination (the \u201ctransaction\u201d) with MSP Recovery, LLC. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44237","6":"format-standard","7":"category-industry"},"yoast_head":"\nMSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MSP Recovery, Inc. to Trade on Nasdaq Under the Symbol \u201cMSPR\u201d Starting May 24 CORAL GABLES, Fla.–(BUSINESS WIRE)–MSP Recovery, Inc. (\u201cMSPR\u201d), formerly known as Lionheart Acquisition Corporation II, a Delaware corporation (Nasdaq: LCAPU, LCAP, LCAPW, \u201cLionheart\u201d or \u201cLCAP\u201d), today announced that it has closed the previously announced business combination (the \u201ctransaction\u201d) with MSP Recovery, LLC. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-23T20:01:18+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC.\",\"datePublished\":\"2022-05-23T20:01:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/\"},\"wordCount\":1822,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/\",\"name\":\"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-05-23T20:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/","og_locale":"en_US","og_type":"article","og_title":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend","og_description":"MSP Recovery, Inc. to Trade on Nasdaq Under the Symbol \u201cMSPR\u201d Starting May 24 CORAL GABLES, Fla.–(BUSINESS WIRE)–MSP Recovery, Inc. (\u201cMSPR\u201d), formerly known as Lionheart Acquisition Corporation II, a Delaware corporation (Nasdaq: LCAPU, LCAP, LCAPW, \u201cLionheart\u201d or \u201cLCAP\u201d), today announced that it has closed the previously announced business combination (the \u201ctransaction\u201d) with MSP Recovery, LLC. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-23T20:01:18+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC.","datePublished":"2022-05-23T20:01:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/"},"wordCount":1822,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/","url":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/","name":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC. - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-05-23T20:01:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/msp-recovery-inc-announces-completion-of-business-combination-between-lionheart-acquisition-corporation-ii-and-msp-recovery-llc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MSP Recovery, Inc. Announces Completion of Business Combination Between Lionheart Acquisition Corporation II and MSP Recovery, LLC."}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44237"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44237\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}